phrykt

Celcuity Inc. (CELC): who owns it and who trades it

As of Nov 16, 2026, CELC insiders reported 17 open-market sales worth $328M and no purchases in the last 12 months, with 3% of the sale value made under pre-set 10b5-1 plans. The largest seller was Julian Baker (Other), with $318M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Celcuity

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CELC

274 funds and institutions reported CELC shares worth $6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 16.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP16.4%
Avoro Capital Advisors LLC7.0%
Rtw Investments, LP6.8%
Perceptive Advisors LLC6.6%
BlackRock, Inc.6.2%
State Street Corp4.0%
Vanguard Capital Management LLC3.9%
NEA Management Company, LLC3.5%
Soleus Capital Management, L.P.3.5%
Bank of America Corp3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP7.92M16.38%$828MNo change
Avoro Capital Advisors LLC3.40M7.03%$356M+1%
Rtw Investments, LP3.30M6.84%$346M+9%
Perceptive Advisors LLC3.20M6.61%$334M+2%
BlackRock, Inc.3.02M6.25%$316M+11%
State Street Corp1.96M4.05%$205M+29%
Vanguard Capital Management LLC1.87M3.88%$196M+5%
NEA Management Company, LLC1.71M3.54%$179M-25%
Soleus Capital Management, L.P.1.70M3.53%$178M+33%
Bank of America Corp1.47M3.04%$154M+106%
Deerfield Management Company, L.P.1.45M3.00%$152M-15%
Morgan Stanley1.33M2.76%$140M-1%
Tang Capital Management LLC1.31M2.72%$138M+25%
Toronto Dominion Bank1.26M2.60%$132M+43%
Geode Capital Management, LLC1.11M2.30%$116M+25%
T. Rowe Price Associates1.03M2.12%$107M-20%
Wellington Management Group LLP906,5951.88%$94.8M+111%
Goldman Sachs Group Inc870,4491.80%$91.1M+14%
Point72 Asset Management, L.P.650,9161.35%$68.1M+132%
Hood River Capital Management LLC628,4111.30%$65.7M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CELC insiders reported $0 of open-market purchases and $328M of sales. 3% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$328M
17 trades, 3 people
Sales under a 10b5-1 plan
3%
Share of sale value
Latest trade
Jul 14, 2026
Filed Jul 16, 2026

Purchases and sales by month

$318M$318MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 14, 2026Julian Baker +3OtherSale2.84M$102.50$291MForm 4
Jul 14, 2026Julian Baker +3OtherSale261,368$102.50$26.8MForm 4
May 4, 2026David DalveyDirectorSale plan25,000$140.68$3.5MForm 4
May 4, 2026Richard E BullerDirectorSale plan2,825$142.04$401KForm 4
May 4, 2026Richard E BullerDirectorSale plan2,301$141.03$325KForm 4
May 4, 2026Richard E BullerDirectorSale plan1,670$139.58$233KForm 4
May 4, 2026Richard E BullerDirectorSale plan550$139.00$76.5KForm 4
May 4, 2026Richard E BullerDirectorSale plan1,289$137.00$177KForm 4
May 4, 2026Richard E BullerDirectorSale plan365$143.24$52.3KForm 4
Mar 31, 2026Richard E BullerDirectorSale plan2,325$110.11$256KForm 4
Mar 31, 2026Richard E BullerDirectorSale plan675$110.83$74.8KForm 4
Jan 27, 2026David DalveyDirectorSale plan20,000$120.03$2.4MForm 4
Dec 5, 2025Richard E BullerDirectorSale1,490$105.34$157KForm 4
Dec 5, 2025Richard E BullerDirectorSale1,510$106.04$160KForm 4
Dec 1, 2025Richard E BullerDirectorSale1,100$98.13$108KForm 4
Nov 21, 2025David DalveyDirectorSale plan15,000$100.00$1.5MForm 4
Nov 20, 2025Richard E BullerDirectorSale3,900$96.73$377KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Julian BakerOther–$318MJul 14, 2026
David DalveyDirector–$7.4MMay 4, 2026
Richard E BullerDirector–$2.4MMay 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CELC short interest

Very high short interest. 21.0% of CELC shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 8%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.30M CELC shares were sold short, 21.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 1.76M shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short, % of all shares

21.0%May 15Oct 3023.7%

Days to cover

5.8May 15Oct 3017.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.30M20.97%+0%1.76M5.8
Oct 15, 202610.25M20.95%-7%1.78M5.8
Sep 30, 202610.98M22.44%-3%995,70311.0
Sep 15, 202611.36M23.22%+6%910,32712.5
Aug 31, 202610.69M21.84%+1%679,96915.7
Aug 14, 202610.54M21.53%+3%796,59213.2
Jul 31, 202610.26M21.23%-8%1.52M6.8
Jul 15, 202611.15M23.07%+2%1.97M5.7
Jun 30, 202610.97M22.69%+3%1.28M8.6
Jun 15, 202610.67M22.07%+11%2.45M4.3
May 29, 20269.60M19.86%+0%795,12012.1
May 15, 20269.56M19.77%+7%1.60M6.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Celcuity company events

Celcuity filed 16 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 2, 2026LeadershipThe Board of Directors of Celcuity Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from eight members to nine members and to appoint David W. Gryska as a new director to fill the resulting vacancy, effective… Filing
  3. Sep 30, 2026AnnouncementThe Company issued a press release announcing that REVTORPYK is now commercially available in the United States for eligible patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic… Filing
  4. Aug 26, 2026AnnouncementThe Company issued a press release announcing the submission of its sNDA to the FDA for REVTORPYK for the treatment of patients with HR+/HER2- ABC with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy. Filing
  5. Aug 13, 2026ResultsReleased financial results. Filing
  6. Jul 15, 2026AnnouncementAmended an earlier report. The Company issued a press release announcing FDA approval of REVTORPYK for the treatment of patients with HR+/HER2-, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the… Filing
  7. Jul 15, 2026AnnouncementThe Company issued a press release announcing FDA approval of REVTORPYK for the treatment of patients with HR+/HER2-, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the… Filing
  8. Jun 8, 2026AgreementCelcuity Inc. entered into an underwriting agreement with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, agreeing, subject to customary conditions, to issue and sell in a public… Filing
  9. Jun 2, 2026AnnouncementThe Company announced detailed efficacy and safety results from the PIK3CA MT cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive, human epidermal growth factor receptor 2 negative, PIK3CA MT… Filing
  10. May 20, 2026LeadershipAmended an earlier report. The Board of Directors of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy… Filing
  11. May 18, 2026LeadershipCelcuity Inc. held its 2026 Annual Meeting of Stockholders. Filing
  12. May 14, 2026ResultsReleased financial results. Filing
  13. May 1, 2026AnnouncementThe Company issued a press release announcing positive topline results from the PIK3CA mutant cohort of the VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- ABC, following progression on or after treatment with a CDK4/6 inhibitor and… Filing
  14. Mar 25, 2026ResultsReleased financial results. Filing
  15. Feb 12, 2026LeadershipThe Board of Directors of Celcuity Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy… Filing
  16. Nov 17, 2025AnnouncementThe Company issued a press release announcing the submission of its NDA to the FDA for gedatolisib in HR+/HER2- PIK3CA wild-type ABC. Item 9.01 Financial Statements and Exhibits. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Celcuity financials

Famous investors that hold CELC

4 of the 50 well-known investors we track reported holding CELC in their latest 13F filing. The largest position is Steve Cohen's, worth $140M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.76M$140M0.2%+171%
Ken Griffin · Citadel AdvisorsQ3 2026600,374$47.7M0.0%New
Israel Englander · Millennium ManagementQ3 202666,701$5.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202624,094$1.9M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CELC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Avoro Capital Advisors LLC13G/A3.1%
Nov 16, 2026BANK OF AMERICA CORP /DE/13G/A3.7%
Nov 16, 2026BANK OF AMERICA CORP /DE/13G/A3.7%
Nov 16, 2026Avoro Capital Advisors LLC13G/A3.1%

Questions about Celcuity Inc. (CELC) stock

Who owns the most CELC stock?

The largest reported owner of Celcuity Inc. (CELC) is Baker Bros. Advisors LP, with 16.4% of the company. In total, 274 funds and institutions reported holding CELC at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CELC insiders buying or selling?

In the last 12 months, CELC insiders reported no open-market purchases and 17 sales worth $328M. The latest trade was on Jul 14, 2026. See every trade.

What is the short interest in CELC?

As of Oct 30, 2026, 10.30M CELC shares were sold short, 21.0% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 1.76M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Which famous investors hold CELC?

4 of the 50 well-known investors we track reported CELC in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $140M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.